The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma

被引:36
作者
AvallLundqvist, EH
Silfversward, C
Aspenblad, U
Nilsson, BR
Auer, GU
机构
[1] KAROLINSKA HOSP & INST,DEPT TUMOR PATHOL,S-17176 STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP & INST,DEPT CANC EPIDEMIOL & BIOSTAT,S-17176 STOCKHOLM,SWEDEN
关键词
cervical carcinoma; immunohistochemistry; tumour angiogenesis; MID-1; p53;
D O I
10.1016/S0959-8049(97)00161-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour angiogenesis (antifactor VIII-related antigen antibody), p53 overexpression (DO-1) and proliferative activity (MIB-1) were immunohistochemically analysed for the prediction of long-term survival in 113 patients with squamous cervical carcinoma. The median follow-up time was 82 months (range 72-99). In early stages (IB-IIA), neovascularisation was significantly related to tumour size. Significantly more patients in stage IIA had high tumour vascularity compared to stage IB (P < 0.01) but no significant difference was found between early and advanced stages (IIB-IVB) Of cervical carcinoma. p53 overexpression was correlated to the stage of disease (P < 0.01). No relationship was found between tumour angiogenesis, p53 overexpression or MIB-1 and pelvic lymph node metastases, histological subtype or differentiation. Tumours with more than 50% p53 overexpression was significantly correlated with survival in the univariate analysis, but no independent predictive value was found. It is concluded that immunohistochemically detectable p53 overexpression as measured by DO-1 and proliferative activity as measured by MIB-1 seems of no clinical value for the prediction of long-term survival in squamous cervical carcinoma. The predictive value of tumour angiogenesis for survival outcome has still to be determined in squamous cervical carcinoma. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:1799 / 1804
页数:6
相关论文
共 36 条
[1]   PROGNOSTIC-SIGNIFICANCE OF PRETREATMENT SERUM LEVELS OF SQUAMOUS-CELL CARCINOMA ANTIGEN AND CA125 IN CERVICAL-CARCINOMA [J].
AVALLLUNDQVIST, EH ;
SJOVALL, K ;
NILSSON, BR ;
ENEROTH, PHE .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (10) :1695-1702
[2]   Tumor angiogenesis: An independent prognostic parameter in cervical cancer [J].
Bremer, GL ;
Tiebosch, ATMG ;
vanderPutten, HWHM ;
Schouten, HJA ;
deHaan, J ;
Arends, JW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (01) :126-131
[3]  
Broders AC, 1926, ARCH PATHOL LAB MED, V2, P376
[4]   MONOCLONAL-ANTIBODIES AGAINST RECOMBINANT PARTS OF THE KI-67 ANTIGEN (MIB-1 AND MIB-3) DETECT PROLIFERATING CELLS IN MICROWAVE-PROCESSED FORMALIN-FIXED PARAFFIN SECTIONS [J].
CATTORETTI, G ;
BECKER, MHG ;
KEY, G ;
DUCHROW, M ;
SCHLUTER, C ;
GALLE, J ;
GERDES, J .
JOURNAL OF PATHOLOGY, 1992, 168 (04) :357-363
[5]   CARCINOMA OF THE CERVIX UTERI - AN ASSESSMENT OF THE RELATIONSHIP OF TUMOR PROLIFERATION TO PROGNOSIS [J].
COLE, DJ ;
BROWN, DC ;
CROSSLEY, E ;
ALCOCK, CJ ;
GATTER, KC .
BRITISH JOURNAL OF CANCER, 1992, 65 (05) :783-785
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   CLINICAL PROGNOSTIC-SIGNIFICANCE OF TUMOR ANGIOGENESIS [J].
CRAFT, PS ;
HARRIS, AL .
ANNALS OF ONCOLOGY, 1994, 5 (04) :305-311
[8]   IMMUNOHISTOCHEMICAL EXPRESSION OF THE MUTANT P53 PROTEIN AND NUCLEAR-DNA CONTENT DURING THE TRANSITION FROM BENIGN TO MALIGNANT BREAST DISEASE [J].
ERIKSSON, ET ;
SCHIMMELPENNING, H ;
ASPENBLAD, U ;
ZETTERBERG, A ;
AUER, GU .
HUMAN PATHOLOGY, 1994, 25 (11) :1228-1233
[9]   PROBLEMS WITH P53 IMMUNOHISTOCHEMICAL STAINING - THE EFFECT OF FIXATION AND VARIATION IN THE METHODS OF EVALUATION [J].
FISHER, CJ ;
GILLETT, CE ;
VOJTESEK, B ;
BARNES, DM ;
MILLIS, RR .
BRITISH JOURNAL OF CANCER, 1994, 69 (01) :26-31
[10]   MIB-1 IMMUNOSTAINING IN STAGE-I SQUAMOUS CERVICAL-CARCINOMA - RELATIONSHIP WITH NATURAL-KILLER-CELL ACTIVITY [J].
GARZETTI, GG ;
CIAVATTINI, A ;
LUCARINI, G ;
GOTERI, G ;
DENICTOLIS, M ;
MUZZIOLI, M ;
FABRIS, N ;
ROMANINI, C ;
BIAGINI, G .
GYNECOLOGIC ONCOLOGY, 1995, 58 (01) :28-33